The estimated Net Worth of Fenel M Eloi is at least $53.9 Thousand dollars as of 12 June 2024. Fenel Eloi owns over 7,777 units of 908 Devices stock worth over $53,921 and over the last 4 years Fenel sold MASS stock worth over $0.
Fenel has made over 6 trades of the 908 Devices stock since 2022, according to the Form 4 filled with the SEC. Most recently Fenel exercised 7,777 units of MASS stock worth $27,142 on 12 June 2024.
The largest trade Fenel's ever made was exercising 7,777 units of 908 Devices stock on 12 June 2024 worth over $27,142. On average, Fenel trades about 1,931 units every 105 days since 2021. As of 12 June 2024 Fenel still owns at least 15,450 units of 908 Devices stock.
You can see the complete history of Fenel Eloi stock trades at the bottom of the page.
Fenel's mailing address filed with the SEC is C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON, MA, 02210.
Over the last 4 years, insiders at 908 Devices have traded over $16,182,689 worth of 908 Devices stock and bought 826,585 units worth $15,798,345 . The most active insiders traders include Keith Crandell, Kevin J. Knopp, and E Kevin Hrusovsky. On average, 908 Devices executives and independent directors trade stock every 10 days with the average trade being worth of $64,663. The most recent stock trade was executed by Christopher D. Brown on 7 August 2024, trading 6,328 units of MASS stock currently worth $9,998.
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. It operates in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.
908 Devices executives and other stock owners filed with the SEC include: